Medinet and MaxCyte initiate cancer collaboration

Under the agreement, MaxCyte will optimize its proprietary cell loading system for the development of Medinet’s novel cancer immuno-cell therapy and implementation in a closed-system manufacturing process at Medinet’s four cell processing centers in Japan.

MaxCyte and Medinet have also agreed to key terms for a commercial license to MaxCyte’s cell loading system to support clinical studies and commercialization of Medinet’s immunotherapy product.

MaxCyte claims that its proprietary ex vivo cell loading technology overcomes critical obstacles, such as safety, scalability, and reproducibility, which are fundamental to successful cell-based therapies. The company has so far used this technology to build a pipeline of six partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases, as well as developing several drug candidates in collaboration with leading researchers.

“We are developing a novel cancer immunotherapy approach using cells from the patient’s own immune system and believe that the MaxCyte system can be a key enabling technology in our manufacturing process,” said Yoshiji Kimura, Medinet’s CEO. “We believe this therapeutic shows great potential and we are excited to enter into this relationship with MaxCyte.”